Literature DB >> 17937428

Homozygosity for a novel splice site mutation in the cardiac myosin-binding protein C gene causes severe neonatal hypertrophic cardiomyopathy.

Baozhong Xin1, Erik Puffenberger, John Tumbush, J R Bockoven, Heng Wang.   

Abstract

Hypertrophic cardiomyopathy is typically inherited in an autosomal dominant pattern and has a variable age of onset and prognosis. Mutations in the myosin-binding protein C (MYBPC3) gene are one of the most frequent genetic causes of the disease. Patients with MYBPC3 mutations generally have a late onset and a relatively good prognosis. We report here more than 20 Old Order Amish children with severe neonatal hypertrophic cardiomyopathy caused by a novel homozygous splice site mutation in the MYBPC3 gene. The affected children typically presented with signs and symptoms of congestive heart failure during the first 3 weeks of life. Echocardiography revealed hypertrophic non-obstructive cardiomyopathy. These children had a life span averaging 3-4 months. All patients died from heart failure before 1 year of age unless they received a heart transplant. A genome-wide mapping study was performed in three patients. The disease related gene was localized to a 4.6 Mb region on chromosome 11p11.2-p11.12. This homozygous block contained MYBPC3, a previously identified cardiomyopathy related gene. We identified a novel homozygous mutation, c.3330 + 2T > G, in the splice-donor site of MYBPC3 intron 30. The mutation resulted in skipping of the 140-bp exon 30, which led to a frame shift and premature stop codon in exon 31 (p.Asp1064GlyfsX38). We have found a substantial incidence of this phenotype in Old Order Amish communities. It is also concerning that many unidentified heterozygous individuals who are at risk for development of hypertrophic cardiomyopathy do not receive proper medical attention in the communities. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17937428     DOI: 10.1002/ajmg.a.31981

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  24 in total

1.  Subclinical echocardiographic abnormalities in phenotype-negative carriers of myosin-binding protein C3 gene mutation for hypertrophic cardiomyopathy.

Authors:  Sabe De; Allen G Borowski; Heng Wang; Leah Nye; Baozhong Xin; James D Thomas; W H Wilson Tang
Journal:  Am Heart J       Date:  2011-07-18       Impact factor: 4.749

2.  Evaluation of the Mayo Clinic Phenotype-Based Genotype Predictor Score in Patients with Clinically Diagnosed Hypertrophic Cardiomyopathy.

Authors:  Sinead L Murphy; Jason H Anderson; Jamie D Kapplinger; Teresa M Kruisselbrink; Bernard J Gersh; Steve R Ommen; Michael J Ackerman; J Martijn Bos
Journal:  J Cardiovasc Transl Res       Date:  2016-02-25       Impact factor: 4.132

3.  Effects of MYBPC3 loss-of-function mutations preceding hypertrophic cardiomyopathy.

Authors:  Adam S Helms; Vi T Tang; Thomas S O'Leary; Sabrina Friedline; Mick Wauchope; Akul Arora; Aaron H Wasserman; Eric D Smith; Lap Man Lee; Xiaoquan W Wen; Jordan A Shavit; Allen P Liu; Michael J Previs; Sharlene M Day
Journal:  JCI Insight       Date:  2020-01-30

Review 4.  Research priorities in sarcomeric cardiomyopathies.

Authors:  Jolanda van der Velden; Carolyn Y Ho; Jil C Tardiff; Iacopo Olivotto; Bjorn C Knollmann; Lucie Carrier
Journal:  Cardiovasc Res       Date:  2015-01-28       Impact factor: 10.787

5.  Identification of Two Novel ERCC6 Mutations in Old Order Amish with Cockayne Syndrome.

Authors:  B Xin; H Wang
Journal:  Mol Syndromol       Date:  2012-12-21

6.  Three-dimensional speckle tracking echocardiography for the preclinical diagnosis of hypertrophic cardiomyopathy.

Authors:  Mohamed F A Aly; Wessel P Brouwer; Sebastiaan A Kleijn; Albert C van Rossum; Otto Kamp
Journal:  Int J Cardiovasc Imaging       Date:  2014-01-30       Impact factor: 2.357

7.  Compound heterozygous or homozygous truncating MYBPC3 mutations cause lethal cardiomyopathy with features of noncompaction and septal defects.

Authors:  Marja W Wessels; Johanna C Herkert; Ingrid M Frohn-Mulder; Michiel Dalinghaus; Arthur van den Wijngaard; Ronald R de Krijger; Michelle Michels; Irenaeus Fm de Coo; Yvonne M Hoedemaekers; Dennis Dooijes
Journal:  Eur J Hum Genet       Date:  2014-10-22       Impact factor: 4.246

Review 8.  Cardiac myosin-binding protein C (MYBPC3) in cardiac pathophysiology.

Authors:  Lucie Carrier; Giulia Mearini; Konstantina Stathopoulou; Friederike Cuello
Journal:  Gene       Date:  2015-09-08       Impact factor: 3.688

9.  Homozygous frameshift mutation in TMCO1 causes a syndrome with craniofacial dysmorphism, skeletal anomalies, and mental retardation.

Authors:  Baozhong Xin; Erik G Puffenberger; Susan Turben; Haiyan Tan; Aimin Zhou; Heng Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-14       Impact factor: 11.205

10.  Sarcomere mutation-specific expression patterns in human hypertrophic cardiomyopathy.

Authors:  Adam S Helms; Frank M Davis; David Coleman; Sarah N Bartolone; Amelia A Glazier; Francis Pagani; Jaime M Yob; Sakthivel Sadayappan; Ellen Pedersen; Robert Lyons; Margaret V Westfall; Richard Jones; Mark W Russell; Sharlene M Day
Journal:  Circ Cardiovasc Genet       Date:  2014-07-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.